vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是RESOURCES CONNECTION, INC.的1.3倍（$156.4M vs $117.7M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs -19.2%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs -11.8%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
BCRX vs RGP — 直观对比
营收规模更大
BCRX
是对方的1.3倍
$117.7M
营收增速更快
BCRX
高出26.6%
-19.2%
两年增速更快
BCRX
近两年复合增速
-11.8%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $117.7M |
| 净利润 | — | $-12.7M |
| 毛利率 | — | 37.1% |
| 营业利润率 | 13.6% | -10.3% |
| 净利率 | — | -10.8% |
| 营收同比 | 7.5% | -19.2% |
| 净利润同比 | — | 81.6% |
| 每股收益（稀释后） | $0.00 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXRGP
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $117.7M | ||
| Q3 25 | $159.4M | $120.2M | ||
| Q2 25 | $163.4M | $139.3M | ||
| Q1 25 | $145.5M | $129.4M | ||
| Q4 24 | $131.5M | $145.6M | ||
| Q3 24 | $117.1M | $136.9M | ||
| Q2 24 | $109.3M | $148.2M |
净利润BCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $-12.7M | ||
| Q3 25 | $12.9M | $-2.4M | ||
| Q2 25 | $5.1M | $-73.3M | ||
| Q1 25 | $32.0K | $-44.1M | ||
| Q4 24 | $-26.8M | $-68.7M | ||
| Q3 24 | $-14.0M | $-5.7M | ||
| Q2 24 | $-12.7M | $10.5M |
毛利率BCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 37.1% | ||
| Q3 25 | 98.6% | 39.5% | ||
| Q2 25 | 98.3% | 40.2% | ||
| Q1 25 | 96.9% | 35.1% | ||
| Q4 24 | 95.4% | 38.5% | ||
| Q3 24 | 97.3% | 36.5% | ||
| Q2 24 | 98.4% | 40.2% |
营业利润率BCRXRGP
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | -10.3% | ||
| Q3 25 | 18.6% | -1.7% | ||
| Q2 25 | 18.2% | -47.0% | ||
| Q1 25 | 14.6% | -38.4% | ||
| Q4 24 | -3.4% | -52.7% | ||
| Q3 24 | 6.6% | -3.5% | ||
| Q2 24 | 8.0% | 7.6% |
净利率BCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | -10.8% | ||
| Q3 25 | 8.1% | -2.0% | ||
| Q2 25 | 3.1% | -52.6% | ||
| Q1 25 | 0.0% | -34.0% | ||
| Q4 24 | -20.4% | -47.2% | ||
| Q3 24 | -12.0% | -4.2% | ||
| Q2 24 | -11.6% | 7.1% |
每股收益（稀释后）BCRXRGP
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $-0.38 | ||
| Q3 25 | $0.06 | $-0.07 | ||
| Q2 25 | $0.02 | $-2.21 | ||
| Q1 25 | $0.00 | $-1.34 | ||
| Q4 24 | $-0.13 | $-2.08 | ||
| Q3 24 | $-0.07 | $-0.17 | ||
| Q2 24 | $-0.06 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $194.6M |
| 总资产 | $465.1M | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXRGP
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $89.8M | ||
| Q3 25 | $212.9M | $77.5M | ||
| Q2 25 | $260.0M | $86.1M | ||
| Q1 25 | $295.1M | $72.5M | ||
| Q4 24 | $320.9M | $78.2M | ||
| Q3 24 | $96.8M | $89.6M | ||
| Q2 24 | $78.4M | $108.9M |
股东权益BCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $194.6M | ||
| Q3 25 | $-387.9M | $206.4M | ||
| Q2 25 | $-421.6M | $207.1M | ||
| Q1 25 | $-451.9M | $277.8M | ||
| Q4 24 | $-475.9M | $325.7M | ||
| Q3 24 | $-468.6M | $407.2M | ||
| Q2 24 | $-475.6M | $418.8M |
总资产BCRXRGP
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $289.3M | ||
| Q3 25 | $446.4M | $287.2M | ||
| Q2 25 | $457.2M | $304.7M | ||
| Q1 25 | $480.0M | $375.6M | ||
| Q4 24 | $490.4M | $424.9M | ||
| Q3 24 | $491.3M | $512.9M | ||
| Q2 24 | $472.4M | $510.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $15.9M |
| 自由现金流经营现金流 - 资本支出 | — | $15.6M |
| 自由现金流率自由现金流/营收 | — | 13.2% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $24.3M |
8季度趋势，按日历期对齐
经营现金流BCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $15.9M | ||
| Q3 25 | $41.6M | $-7.8M | ||
| Q2 25 | $41.3M | $16.8M | ||
| Q1 25 | $-27.5M | $659.0K | ||
| Q4 24 | $-5.2M | $1.8M | ||
| Q3 24 | $8.2M | $-309.0K | ||
| Q2 24 | $-1.4M | $3.2M |
自由现金流BCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $15.6M | ||
| Q3 25 | $40.3M | $-8.0M | ||
| Q2 25 | $41.1M | $16.5M | ||
| Q1 25 | $-27.7M | $238.0K | ||
| Q4 24 | $-5.9M | $61.0K | ||
| Q3 24 | $8.2M | $-575.0K | ||
| Q2 24 | $-1.5M | $3.0M |
自由现金流率BCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | 13.2% | ||
| Q3 25 | 25.3% | -6.6% | ||
| Q2 25 | 25.2% | 11.8% | ||
| Q1 25 | -19.0% | 0.2% | ||
| Q4 24 | -4.5% | 0.0% | ||
| Q3 24 | 7.0% | -0.4% | ||
| Q2 24 | -1.4% | 2.1% |
资本支出强度BCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 0.3% | ||
| Q3 25 | 0.8% | 0.1% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.1% | 0.3% | ||
| Q4 24 | 0.5% | 1.2% | ||
| Q3 24 | 0.1% | 0.2% | ||
| Q2 24 | 0.1% | 0.1% |
现金转化率BCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.30× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
